Medical cannabis: therapeutic uses, administration, risks, and legal status

Therapeutic uses and examples

• Antiemetic effects: certain cannabis preparations are used to reduce nausea (nausea) and vomiting (vomiting) associated with chemotherapy for cancer patients.
• Appetite stimulation: cannabinoids have been shown to improve appetite (appetite) and counteract wasting in people with HIV (HIV) or AIDS.
• Pain and spasticity: chronic (chronic) neuropathic and nociceptive pain syndromes and muscle (muscle) spasms are among the most commonly cited indications.

Forms of administration

Medical cannabis is available in multiple delivery formats. Common routes include inhalation (smoking dried flower or vaporizing), oral ingestion (edibles and oils), and measured pharmaceutical forms such as capsules or lozenges. Delivery method affects onset, duration and dosing precision: inhaled products act quickly but vary with inhalation technique, while oral preparations have slower onset and more variable absorption.

Known effects and safety considerations

Short-term effects may include drowsiness, dizziness and perceptual changes; some users report hallucinations (hallucinations) at higher doses. Long-term consequences remain incompletely defined; concerns raised in clinical and epidemiological studies include memory (memory) and cognitive effects, potential for dependence and misuse (addiction), and accidental ingestion by children. The balance of benefit versus risk depends on product composition (for example, differing ratios of psychoactive THC and non-intoxicating CBD), dose, frequency of use and the underlying condition. The use of cannabis in medicine is viewed as controversial in many professional and policy settings because evidence strength varies by indication.

History, regulation and legal status

Humans have used cannabis for medicinal and ritual purposes for thousands of years; modern clinical interest revived in the late 20th and early 21st centuries as constituents were identified and small clinical trials appeared. Legal frameworks differ markedly between jurisdictions: some countries permit medical programs, others restrict all uses. Examples of national approaches include regulated programs in the Czech Republic, Canada, Austria, the Netherlands, Italy and Germany. Legislative change has been proposed or enacted in places such as Australia. In the United States, federal law still classifies cannabis as illegal, but many states implement medical programs and typically do not arrest registered patients who comply with state rules.

Clinicians and patients considering medical cannabis should evaluate product quality, clear diagnostic indication, potential drug interactions, and local regulatory requirements. Standardized dosing, monitoring for adverse effects, and preference for evidence-based formulations where available can improve safety. As research continues and regulatory frameworks evolve, clinical guidance and product availability are likely to change over time.